Allon granted important U.S. patent for preclinical compound AL-408

04-Oct-2011 - Canada

Allon Therapeutics Inc. announced that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The D-isomer of davunetide is known as AL-408 in the company’s pipeline. This new patent strengthens Allon’s intellectual property estate which includes 15 patent families, 58 issued patents and over 30 pending applications worldwide.

Previous pre-clinical studies have demonstrated that AL-408 shows potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity. In an animal model of fetal alcohol syndrome, AL-408 increased survival and improved cognitive performance1. AL-408 has also shown potential neuroprotective activity in a preclinical model of amyotrophic lateral sclerosis (ALS)2.

Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said this new U.S. patent provides protection for an important early-stage compound within the Company’s product pipeline. “Allon’s technology platform of neuroprotective peptides derived from naturally occurring brain proteins shows broad neuroprotective effects in a variety of diseases and conditions”, explains Stewart. “AL-408 has shown some interesting early-stage research results in areas outside of neurodegenerative diseases, further diversifying and adding value to our product pipeline.”

Allon’s patent portfolio also includes issued patents and pending patent applications that provide protection around davunetide and its technology platform for treatment of neurodegenerative diseases, including progressive supranuclear palsy (PSP), Alzheimer’s disease, and Parkinson’s disease.

https://www.bionity.com/en/news/134628/allon-granted-important-u-s-patent-for-preclinical-compound-al-408.html